Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

| Create an account https://orcid.org

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 274 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.
Mazzone PJ, Bach PB, Carey J, Schonewolf CA, Bognar K, Ahluwalia MS, Cruz-Correa M, Gierada D, Kotagiri S, Lloyd K, Maldonado F, Ortendahl JD, Sequist LV, Silvestri GA, Tanner N, Thompson JC, Vachani A, Wong KK, Zaidi AH, [...] Pike LRG
Cancer Discov, 14(11):2224-2242, 01 Nov 2024
Cited by: 1 article | PMID: 38829053 | PMCID: PMC11528203
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm.
Simon J, Mikhael P, Graur A, Chang AEB, Skates SJ, Osarogiagbon RU, Sequist LV, Fintelmann FJ
Invest Radiol, 23 Oct 2024
Cited by: 0 articles | PMID: 39437009
Add to export list
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.
Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, [...] Haber DA
Nat Cancer, 15 Oct 2024
Cited by: 0 articles | PMID: 39406916
Add to export list
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, Jänne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H
Oncologist, 29(7):609-618, 01 Jul 2024
Cited by: 5 articles | PMID: 38761385 | PMCID: PMC11224994
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, Ardizzoni A, Lee DH, Sequist LV, Barlesi F, Ponce-Aix S, Abreu DR, Campelo MRG, Sprauten M, Djentuh LO, Smith N, Jary A, Belli R, Glaser S, [...] Yang JC
Eur J Cancer, 208:114182, 22 Jun 2024
Cited by: 0 articles | PMID: 38986421
Add to export list
Early Detection and Interception of Lung Cancer.
Chang AEB, Potter AL, Yang CJ, Sequist LV
Hematol Oncol Clin North Am, 38(4):755-770, 08 May 2024
Cited by: 0 articles | PMID: 38724286
Add to export list Review
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
Potter AL, Xu NN, Senthil P, Srinivasan D, Lee H, Gazelle GS, Chelala L, Zheng W, Fintelmann FJ, Sequist LV, Donington J, Palmer JR, Yang CJ
J Clin Oncol, 42(17):2026-2037, 27 Mar 2024
Cited by: 1 article | PMID: 38537159 | PMCID: PMC11191064
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, [...] Flaherty KT
JCO Precis Oncol, 8:e2300454, 01 Apr 2024
Cited by: 1 article | PMID: 38591867
Add to export list
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Mishra A, Huang S, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman L, Galler I, [...] Toner M
bioRxiv, 14 Mar 2024
Cited by: 0 articles | PPR: PPR823012
Add to export list Preprint
Deploying blood-based cancer screening.
Micalizzi DS, Sequist LV, Haber DA
Science, 383(6681):368-370, 25 Jan 2024
Cited by: 1 article | PMID: 38271495
Add to export list
Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
Sequist LV, Warner ET, Yang CJ
JAMA Oncol, 9(12):1649-1650, 01 Dec 2023
Cited by: 0 articles | PMID: 37883100
Add to export list
Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint.
Sequist LV, Olazagasti C
Radiology, 309(2):e232850, 01 Nov 2023
Cited by: 0 articles | PMID: 37934096
Add to export list
Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography.
Simon J, Mikhael P, Tahir I, Graur A, Ringer S, Fata A, Jeffrey YC, Shepard JA, Jacobson F, Barzilay R, Sequist LV, Pace LE, Fintelmann FJ
Sci Rep, 13(1):18611, 30 Oct 2023
Cited by: 0 articles | PMID: 37903855 | PMCID: PMC10616081
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lung Cancer in Women: The Past, Present, and Future.
Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, Franco I, Odai-Afotey A, Meza K, Swami N, Patel J, Sequist LV
Clin Lung Cancer, 25(1):1-8, 20 Oct 2023
Cited by: 4 articles | PMID: 37940410
Add to export list Review
Germline mutations and developmental mosaicism underlyingEGFR-mutant lung cancer
Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, [...] Haber DA
medRxiv, 29 Sep 2023
Cited by: 0 articles | PPR: PPR733708
Add to export list Preprint
B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.
Dagogo-Jack I, Valiev I, Kotlov N, Belozerova A, Lopareva A, Butusova A, Samarina N, Boyko A, Xiang Z, Johnson M, Degryse S, Keane FK, Sequist LV, Lanuti M, Fowler N, Mino-Kenudson M, Bagaev A
JTO Clin Res Rep, 4(7):100527, 18 May 2023
Cited by: 2 articles | PMID: 37521368 | PMCID: PMC10372172
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, [...] Hata AN
Nature, 620(7973):393-401, 05 Jul 2023
Cited by: 29 articles | PMID: 37407818 | PMCID: PMC10804446
Add to export list Free full text in Europe PMC
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M
J Clin Oncol, 41(16):2869-2876, 01 Jun 2023
Cited by: 11 articles | PMID: 37235976
Add to export list
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.
Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, Do A, Peterson J, Sequist LV, Gainor JF, Lennerz JK, Digumarthy SR
JTO Clin Res Rep, 4(8):100534, 01 Jun 2023
Cited by: 9 articles | PMID: 37533439 | PMCID: PMC10391652
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Artificial Intelligence and Machine Learning in Lung Cancer Screening.
Adams SJ, Mikhael P, Wohlwend J, Barzilay R, Sequist LV, Fintelmann FJ
Thorac Surg Clin, 33(4):401-409, 12 May 2023
Cited by: 4 articles | PMID: 37806742
Add to export list Review
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
Mikhael PG, Wohlwend J, Yala A, Karstens L, Xiang J, Takigami AK, Bourgouin PP, Chan P, Mrah S, Amayri W, Juan YH, Yang CT, Wan YL, Lin G, Sequist LV, Fintelmann FJ, Barzilay R
J Clin Oncol, 41(12):2191-2200, 12 Jan 2023
Cited by: 36 articles | PMID: 36634294 | PMCID: PMC10419602
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DAE, Kurian N, Cantarini M, Jänne PA
Cancer Discov, 13(1):98-113, 01 Jan 2023
Cited by: 43 articles | PMID: 36264123 | PMCID: PMC9827108
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Expanding the Reach and Grasp of Lung Cancer Screening.
Osarogiagbon RU, Yang PC, Sequist LV
Am Soc Clin Oncol Educ Book, 43:e389958, 01 Jan 2023
Cited by: 10 articles | PMID: 37098234
Add to export list
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Cooper AJ, Sequist LV, Lin JJ
Nat Rev Clin Oncol, 19(11):744, 01 Nov 2022
Cited by: 2 articles | PMID: 35971001
Add to export list
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Tan DSW, Kim SW, Ponce Aix S, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, Grohé C, Leighl NB, Riely G, Cui X, Zou M, Ghebremariam S, O'Sullivan-Djentuh L, Belli R, Giovannini M, Kim DW
Eur J Cancer, 172:276-286, 07 Jul 2022
Cited by: 4 articles | PMID: 35810553
Add to export list

1-25 of 274 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.

Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm.

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

Early Detection and Interception of Lung Cancer.

Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

Deploying blood-based cancer screening.

Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.

Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint.

Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography.

Lung Cancer in Women: The Past, Present, and Future.

Germline mutations and developmental mosaicism underlyingEGFR-mutant lung cancer

B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis.

Artificial Intelligence and Machine Learning in Lung Cancer Screening.

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.

Expanding the Reach and Grasp of Lung Cancer Screening.

Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

Partnerships & funding